Medicis Sues Lupin To Halt Generic Acne Drug

Law360, New York (February 3, 2010, 2:44 PM EST) -- Skin health specialist Medicis Pharmaceutical Corp. has hauled Lupin Ltd. into court over the Indian drugmaker's plan to manufacture generic versions of all five approved dosages of acne drug Solodyn.

Medicis filed an amended complaint Tuesday in the U.S. District Court for the District of Maryland, broadening its claims of patent infringement against Mumbai-based Lupin and its U.S. subsidiary Lupin Pharmaceuticals Inc.

Medicis claims Lupin has infringed U.S. Patent Number 5,908,838, covering extended release tablets for acne treatment, by seeking to manufacture a generic Solodyn before...
To view the full article, register now.